<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-05-16" updated="2020-01-02">
  <drugbank-id primary="true">DB01265</drugbank-id>
  <name>Telbivudine</name>
  <description>Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.</description>
  <cas-number>3424-98-4</cas-number>
  <unii>2OC4HKD3SF</unii>
  <average-mass>242.2286</average-mass>
  <monoisotopic-mass>242.090271568</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A2282</ref-id>
        <pubmed-id>18201580</pubmed-id>
        <citation>Matthews SJ: Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007 Dec;29(12):2635-53. doi: 10.1016/j.clinthera.2007.12.032.</citation>
      </article>
      <article>
        <ref-id>A2283</ref-id>
        <pubmed-id>18069753</pubmed-id>
        <citation>Amarapurkar DN: Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007 Dec 14;13(46):6150-5.</citation>
      </article>
      <article>
        <ref-id>A2284</ref-id>
        <pubmed-id>17724496</pubmed-id>
        <citation>Dusheiko G, Danta M: Telbivudine for the treatment of chronic hepatitis B. Drugs Today (Barc). 2007 May;43(5):293-304.</citation>
      </article>
      <article>
        <ref-id>A2285</ref-id>
        <pubmed-id>17722961</pubmed-id>
        <citation>Keam SJ: Telbivudine. Drugs. 2007;67(13):1917-29.</citation>
      </article>
      <article>
        <ref-id>A2286</ref-id>
        <pubmed-id>17477811</pubmed-id>
        <citation>Ruiz-Sancho A, Sheldon J, Soriano V: Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007 May;7(5):751-61.</citation>
      </article>
      <article>
        <ref-id>A2287</ref-id>
        <pubmed-id>15985003</pubmed-id>
        <citation>Marcellin P, Asselah T, Boyer N: Treatment of chronic hepatitis B. J Viral Hepat. 2005 Jul;12(4):333-45.</citation>
      </article>
      <article>
        <ref-id>A2288</ref-id>
        <pubmed-id>15882124</pubmed-id>
        <citation>Han SH: Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005 Apr;14(4):511-9.</citation>
      </article>
      <article>
        <ref-id>A2289</ref-id>
        <pubmed-id>16981973</pubmed-id>
        <citation>Jones R, Nelson M: Novel anti-hepatitis B agents: A focus on telbivudine. Int J Clin Pract. 2006 Oct;60(10):1295-9.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</indication>
  <pharmacodynamics>Telbivudine is a synthetic thymidine nucleoside analogue with activity against hepatitis B virus (HBV). Telbivudine is the unmodified β–L enantiomer of the naturally occurring nucleoside, thymidine. It undergoes phosphorylation via interaction with cellular kinases to form the active metabolite, telbivudine 5'-triphosphate.</pharmacodynamics>
  <mechanism-of-action>Telbivudine 5'–triphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'–triphosphate. This leads to the chain termination of DNA synthesis, thereby inhibiting viral replication. Incorporation of telbivudine 5'–triphosphate into viral DNA also causes DNA chain termination, resulting in inhibition of HBV replication. Telbivudine inhibits anticompliment or second-strand DNA.</mechanism-of-action>
  <toxicity>There is no information on intentional overdose of telbivudine, but one subject experienced an unintentional and asymptomatic overdose. Healthy subjects who received telbivudine doses up to 1800 mg/day for 4 days had no increase in or unexpected adverse events. A maximum tolerated dose for telbivudine has not been determined.</toxicity>
  <metabolism>No metabolites of telbivudine were detected following administration of [14C]–telbivudine in humans. Telbivudine is not a substrate, or inhibitor of the cytochrome P450 (CYP450) enzyme system.</metabolism>
  <absorption>Absorbed following oral administration. Telbivudine absorption and exposure were unaffected when a single 600–mg dose was administered with a high–fat (~55 g), high–calorie (~950 kcal) meal.</absorption>
  <half-life>Approximately 15 hours.</half-life>
  <protein-binding>In vitro binding of telbivudine to human plasma proteins is low (3.3%).</protein-binding>
  <route-of-elimination>Telbivudine is eliminated primarily by urinary excretion of unchanged drug.</route-of-elimination>
  <volume-of-distribution/>
  <clearance>* 7.6 +/- 2.9 L/h [Normal renal function (Clcr&gt;80 mL/min)]&#13;
* 5.0 +/- 1.2 L/h [Mild renal function impairement (Clcr=50-80 mL/min)]&#13;
* 2.6 +/- 1.2 L/h [Moderate renal function impairement (Clcr=30-49 mL/min)]&#13;
* 0.7 +/- 0.4 L/h [Severe renal function impairement (Clcr&lt;30 mL/min)]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.</description>
    <direct-parent>Pyrimidine 2'-deoxyribonucleosides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Nucleosides, nucleotides, and analogues</superclass>
    <class>Pyrimidine nucleosides</class>
    <subclass>Pyrimidine 2'-deoxyribonucleosides</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydropyrimidines</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tetrahydrofurans</alternative-parent>
    <alternative-parent>Ureas</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydropyrimidine</substituent>
    <substituent>Lactam</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidine 2'-deoxyribonucleoside</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tetrahydrofuran</substituent>
    <substituent>Urea</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil</synonym>
    <synonym language="english" coder="">2'-Deoxy-L-thymidine</synonym>
    <synonym language="english" coder="">Beta-l-thymidine</synonym>
    <synonym language="english" coder="">Epavudine</synonym>
    <synonym language="english" coder="">L-deoxythymidine</synonym>
    <synonym language="english" coder="">L-DT</synonym>
    <synonym language="english" coder="">L-thymidine</synonym>
    <synonym language="english" coder="">LDT</synonym>
    <synonym language="english" coder="">Telbivudin</synonym>
    <synonym language="spanish" coder="">Telbivudina</synonym>
    <synonym language="english" coder="inn/usan">Telbivudine</synonym>
    <synonym language="english" coder="">β-L-2'-deoxythymidine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Sebivo</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000713</ema-product-code>
      <ema-ma-number>EU/1/07/388/001</ema-ma-number>
      <started-marketing-on>2007-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>600 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sebivo</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000713</ema-product-code>
      <ema-ma-number>EU/1/07/388/002</ema-ma-number>
      <started-marketing-on>2007-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>600 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sebivo</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000713</ema-product-code>
      <ema-ma-number>EU/1/07/388/003</ema-ma-number>
      <started-marketing-on>2007-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/ml</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Sebivo</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tyzeka</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-25</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>600 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022011</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tyzeka</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>24108-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-06</started-marketing-on>
      <ended-marketing-on>2006-11-06</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>600 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tyzeka</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-28</started-marketing-on>
      <ended-marketing-on>2010-03-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA022154</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Sebivo</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
    <mixture>
      <name>Sebivo</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
    <mixture>
      <name>Sebivo</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
    <mixture>
      <name>Tyzeka</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
    <mixture>
      <name>Tyzeka</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
    <mixture>
      <name>Tyzeka</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
    <mixture>
      <name>Sebivo</name>
      <ingredients>Telbivudine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Idenix Pharmaceutical Inc.</name>
      <url>http://www.idenix.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Tyzeka 600 mg tablet</description>
      <cost currency="USD">27.26</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Antivirals for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Deoxyribonucleosides</category>
      <mesh-id>D003853</mesh-id>
    </category>
    <category>
      <category>Direct Acting Antivirals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nucleic Acid Synthesis Inhibitors</category>
      <mesh-id>D019384</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleoside and Nucleotide Reverse Transcriptase Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nucleoside Reverse Transcriptase Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nucleosides</category>
      <mesh-id>D009705</mesh-id>
    </category>
    <category>
      <category>Nucleosides and Nucleotides</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pyrimidine Nucleosides</category>
      <mesh-id>D011741</mesh-id>
    </category>
    <category>
      <category>Pyrimidines</category>
      <mesh-id>D011743</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Hepatitis B virus</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>20 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>600 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>600 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J05AF11">
      <level code="J05AF">Nucleoside and nucleotide reverse transcriptase inhibitors</level>
      <level code="J05A">DIRECT ACTING ANTIVIRALS</level>
      <level code="J05">ANTIVIRALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:18.32</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>3hp1</pdb-entry>
    <pdb-entry>3qeo</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>2340156</number>
      <country>Canada</country>
      <approved>2007-10-23</approved>
      <expires>2019-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6395716</number>
      <country>United States</country>
      <approved>2002-05-28</approved>
      <expires>2019-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6444652</number>
      <country>United States</country>
      <approved>2002-09-03</approved>
      <expires>2019-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6566344</number>
      <country>United States</country>
      <approved>2003-05-20</approved>
      <expires>2019-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6569837</number>
      <country>United States</country>
      <approved>2003-05-27</approved>
      <expires>2020-10-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7589079</number>
      <country>United States</country>
      <approved>2009-09-15</approved>
      <expires>2023-09-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7795238</number>
      <country>United States</country>
      <approved>2010-09-14</approved>
      <expires>2019-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7858594</number>
      <country>United States</country>
      <approved>2010-12-28</approved>
      <expires>2023-09-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Take without regard to meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Ribavirin may increase the hepatotoxic activities of Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of cytopenia can be increased when Ganciclovir is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>The risk or severity of cytopenia can be increased when Valganciclovir is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Telbivudine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.56</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.68e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>telbivudine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>242.2286</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>242.090271568</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C10H14N2O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>IQFYYKKMVGJFEH-CSMHCCOUSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>99.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>55.41</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>23.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Sparingly soluble in water (&gt;20 mg/mL)</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.4</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20037</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>63624</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>159269</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508706</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D06675</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>140081</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50088372</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164760861</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>LLT</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000698</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Telbivudine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL374731</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/tyzeka.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/telbivudine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000555</id>
      <name>Protein P</name>
      <organism>HBV-F</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A11448</ref-id>
            <pubmed-id>19344240</pubmed-id>
            <citation>Lui YY, Chan HL: Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther. 2009 Apr;7(3):259-68. doi: 10.1586/eri.09.6.</citation>
          </article>
          <article>
            <ref-id>A11449</ref-id>
            <pubmed-id>19225726</pubmed-id>
            <citation>Nash K: Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009 Feb;26(2):155-69. doi: 10.1007/s12325-009-0004-y. Epub 2009 Feb 18.</citation>
          </article>
          <article>
            <ref-id>A11450</ref-id>
            <pubmed-id>18798704</pubmed-id>
            <citation>Lui YY, Chan HL: A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1351-61. doi: 10.1517/17425255.4.10.1351 .</citation>
          </article>
          <article>
            <ref-id>A2283</ref-id>
            <pubmed-id>18069753</pubmed-id>
            <citation>Amarapurkar DN: Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007 Dec 14;13(46):6150-5.</citation>
          </article>
          <article>
            <ref-id>A2285</ref-id>
            <pubmed-id>17722961</pubmed-id>
            <citation>Keam SJ: Telbivudine. Drugs. 2007;67(13):1917-29.</citation>
          </article>
          <article>
            <ref-id>A2286</ref-id>
            <pubmed-id>17477811</pubmed-id>
            <citation>Ruiz-Sancho A, Sheldon J, Soriano V: Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007 May;7(5):751-61.</citation>
          </article>
          <article>
            <ref-id>A2288</ref-id>
            <pubmed-id>15882124</pubmed-id>
            <citation>Han SH: Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005 Apr;14(4):511-9.</citation>
          </article>
          <article>
            <ref-id>A2289</ref-id>
            <pubmed-id>16981973</pubmed-id>
            <citation>Jones R, Nelson M: Novel anti-hepatitis B agents: A focus on telbivudine. Int J Clin Pract. 2006 Oct;60(10):1295-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q05486" source="Swiss-Prot">
        <name>Protein P</name>
        <general-function>Rna-dna hybrid ribonuclease activity</general-function>
        <specific-function>Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse-transcribed inside the nucleocapsid. Initiation of reverse-transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'-end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, the RC-DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery (By similarity).</specific-function>
        <gene-name>P</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>10.12</theoretical-pi>
        <molecular-weight>94257.43</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="45410">HBV-F</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X69798</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>59427</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q05486</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPOL_HBVF1</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.7.7</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010386|Protein P
MPLSYPHFRKLLLLDDEAGPLEEELPRLADEDLNRRVAADLNLQLPNVSIPWTHKVGNFT
GLYSSTVPAFNPNWSTPSFPDIHLHQDLISKCEQFVGPLTKNELRRLKLVMPARFYPKVT
KYFPMDKGIKPYYPEHAVNHYFKTRHYLHTLWKAGILYKRESTRSASFCGSPYSWEQELQ
HGSTSLNDTKRHGTESLCAQSSGILSRPSAGSAIQSKFQQSRLGLQHKQGQLANGKQGRS
GRLRSRVHTPTRWPAGVEPSSTRCVNNLASRSASCFHQSAVREKANPSLSTSKRHTSTGN
AVELNPVPPSSVGSQGKGSVLPCWWLQFRDTEPCSDYCLSHIINLLEDWGPCYEHGQHYI
RTPRTPARVTGGVFLVDKNPHNTTESRLVVDFSQFSRGTTRVSWPKFAVPNLQSLTNLLS
SNLSWLSLDVSAAFYHLPLHPAAMPHLLVGSSGLSRYVARLSSTSRIHDHQHGTLQNLHN
SCTRNLYVSLLLLFQTLGRKLHLYSHPIILGFRKIPMGVGLSPFLLAQFTSAICSVVRRA
FPHCLAFSYMDDLVLGAKSVQHLESLYTAVTNFLLSVGIHLNTSKTKRWGYSLHFMGYVI
GSWGSLPQDHIVHKIKECFRKLPVNRPIDWKVCQRIVGLLGFAAPFTQCGYPALMPLYAC
ITAKQAFVFSPTYKAFLCKQYMNLYPVARQRPGLCQVFADATPTGWGLAIGHQRMRGTFV
APLPIHTAELLAACFARSRSGATLIGTDNSVVLSRKYTSFPWLLGCAANWILRGTSFVYV
PSALNPADDPSRGRLGLYRPLLRLPFQPTTGRTSLYADSPSVPSHLPDRVHFASPLHVAW
RPP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0001107|2532 bp
ATGCCCCTATCCTATCCACACTTCCGGAAACTACTGTTGTTAGACGACGAGGCAGGTCCC
CTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAGATCTCAATCGCCGCGTCGCCGCAGAT
CTCAATCTCCAGCTTCCCAATGTTAGTATTCCTTGGACTCATAAGGTGGGAAACTTTACG
GGGCTTTACTCTTCTACTGTGCCTGCTTTTAATCCTAACTGGTCCACTCCTTCTTTTCCT
GATATTCATTTGCATCAAGACCTGATTTCTAAATGTGAACAATTTGTAGGCCCACTTACT
AAAAATGAATTACGAAGATTAAAATTGGTTATGCCAGCTAGATTTTATCCTAAGGTTACC
AAATATTTTCCCATGGATAAAGGCATCAAACCCTATTATCCTGAGCATGCAGTTAATCAT
TACTTTAAAACCAGACATTATTTGCATACTTTATGGAAGGCGGGAATTTTATATAAGAGA
GAATCCACACGTAGCGCCTCATTTTGTGGGTCACCATATTCCTGGGAACAAGAGCTACAG
CATGGGAGCACCTCTCTCAACGACACGAAGAGGCATGGGACAGAATCTCTCTGTGCCCAA
TCCTCTGGGATTCTTTCCAGACCATCAGCTGGATCCGCTATTCAGAGCAAATTCCAGCAG
TCCCGACTGGGACTTCAACACAAACAAGGACAGTTGGCCAATGGCAAACAAGGTAGGAGT
GGGAGGCTACGGTCCAGGGTTCACACCCCCACACGGTGGCCTGCTGGGGTGGAGCCCTCA
AGCACAAGGTGTGTTAACAACCTTGCCAGCAGATCCGCCTCCTGCTTCCACCAATCGGCG
GTCCGGGAGAAAGCCAACCCCAGTCTCTCCACCTCTAAGAGACACACATCCACAGGCAAT
GCAGTGGAACTCAACCCAGTTCCACCAAGCTCTGTTGGATCCCAGGGTAAGGGCTCTGTA
CTTCCCTGCTGGTGGCTCCAGTTCAGGGACACAGAACCCTGCTCCGACTATTGCCTCTCT
CACATCATCAATCTTCTCGAAGACTGGGGGCCCTGCTATGAACATGGACAACATTACATC
AGGACTCCTAGGACCCCTGCTCGTGTTACAGGCGGTGTGTTTCTTGTTGACAAAAATCCT
CACAATACCACAGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTTCTAGGGGGACTACC
CGGGTGTCCTGGCCAAAATTCGCAGTCCCCAACCTCCAATCACTTACCAACCTCCTGTCC
TCCAACTTGTCCTGGCTATCGTTGGATGTGTCTGCGGCGTTTTATCATCTTCCTCTTCAT
CCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTATCAAGGTATGTTGCCCGT
TTGTCCTCTACTTCCAGGATCCACGACCACCAGCACGGGACCCTGCAAAACCTGCACAAC
TCTTGCACAAGGAACCTCTATGTTTCCCTCCTGTTGCTGTTCCAAACCCTCGGACGGAAA
CTGCACTTGTATTCCCATCCCATCATCCTGGGCTTTAGGAAAATACCTATGGGAGTGGGC
CTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCAATTTGTTCAGTGGTGCGTCGGGCT
TTCCCCCACTGTTTGGCTTTTAGTTATATGGATGATCTGGTATTGGGGGCCAAATCTGTG
CAGCATCTTGAGTCCCTTTATACCGCTGTTACCAATTTTCTGTTATCTGTGGGTATCCAT
TTAAATACCTCTAAAACAAAAAGATGGGGTTACTCCCTACATTTTATGGGTTATGTCATT
GGTAGTTGGGGATCATTACCCCAAGATCACATTGTACACAAAATCAAGGAATGCTTTCGA
AAACTGCCTGTAAATCGTCCAATTGATTGGAAAGTTTGTCAACGCATAGTGGGTCTTTTG
GGCTTTGCTGCCCCTTTCACCCAATGCGGTTATCCTGCTCTCATGCCTCTGTATGCCTGT
ATTACTGCTAAACAGGCTTTTGTCTTCTCGCCAACCTACAAGGCCTTTCTGTGTAAACAA
TACATGAACCTTTACCCGGTTGCTCGGCAACGGCCAGGCCTGTGCCAAGTGTTTGCTGAC
GCAACCCCCACTGGTTGGGGCTTGGCCATTGGCCATCAGCGCATGCGTGGAACCTTTGTG
GCTCCTCTGCCGATCCATACTGCGGAACTCCTAGCAGCTTGTTTCGCTCGCAGCAGGTCT
GGAGCGACTCTCATCGGCACGGACAATTCTGTTGTCCTCTCTAGGAAGTACACCTCCTTT
CCATGGCTGCTCGGATGTGCTGCAAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTC
CCATCGGCGCTGAATCCCGCGGACGACCCCTCCCGGGGCCGCTTGGGGCTGTACCGCCCT
CTTCTCCGTCTGCCGTTCCAGCCGACGACGGGTCGCACCTCTCTTTACGCGGACTCCCCG
TCTGTTCCTTCTCATCTGCCGGACCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGG
AGACCACCGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00336</identifier>
            <name>DNA_pol_viral_C</name>
          </pfam>
          <pfam>
            <identifier>PF00242</identifier>
            <name>DNA_pol_viral_N</name>
          </pfam>
          <pfam>
            <identifier>PF00078</identifier>
            <name>RVT_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-DNA hybrid ribonuclease activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host innate immune response</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A11449</ref-id>
            <pubmed-id>19225726</pubmed-id>
            <citation>Nash K: Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009 Feb;26(2):155-69. doi: 10.1007/s12325-009-0004-y. Epub 2009 Feb 18.</citation>
          </article>
          <article>
            <ref-id>A15456</ref-id>
            <pubmed-id>18063258</pubmed-id>
            <citation>Gaeta GB, Stornaiuolo G: Therapy of chronic hepatitis B: focus on telbivudine. Dig Liver Dis. 2007 Nov;39 Suppl 3:S372-8. doi: 10.1016/S1590-8658(07)60017-6.</citation>
          </article>
          <article>
            <ref-id>A2286</ref-id>
            <pubmed-id>17477811</pubmed-id>
            <citation>Ruiz-Sancho A, Sheldon J, Soriano V: Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007 May;7(5):751-61.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>